Company Overview and News

52
Your Daily Pharma Scoop: Tonix Progresses, J&J Succeeds, Quidel Is Cleared

2018-07-19 seekingalpha
Tonix Pharmaceuticals receives fast track designation for TNX-102 SL for treatment of agitation in alzheimer’s disease
CSCWF NTLA IRWD QDEL OPK KOOL CRSP KOOLW EDIT JNJ SYK NUVA PFE

15
Intuitive Surgical: Potentially Attractive Entry Point Following Any Post-2Q18 Sell Off

2018-07-19 seekingalpha
Intuitive Surgical is experiencing strong operating momentum and positive consensus estimate momentum, and despite its "high" trading multiple we think the stock has upside potential.
JNJ SYK LGNZZ LGND OR LGNYZ LGNXZ ISRG LGNDZ MDT

4
Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

2018-07-18 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
NS.PRC NS.PRB HD TJX SYK NFLX NS NS.PRA ROK

4
Haemonetics Gains on Strong Plasma, Wider Global Footprint

2018-07-17 zacks
On Jul 16, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from a steady momentum in new business generation and geographical expansion. The stock carries a Zacks Rank #2 (Buy).
ALGN SYK HAE GHDX

25
Boston Scientific Is A Solid Buy Opportunity In 2018

2018-07-17 seekingalpha
Endoscopy, Urology, and Pelvic Health segments are proving to be major growth drivers for Boston Scientific in 2018.
ABT BSX JNJ SYK ABT EW MDT GI

2
Here's Why You Should Hold Onto Opko Health (OPK) Stock Now

2018-07-17 zacks
With a market capitalization of approximately $3.28 billion, Opko Health, Inc. (OPK - Free Report) has been riding high on solid prospects in RAYLDEE and BioReference platforms. The company’s consistent focus in R&D bodes well. However, the company faces cutthroat competition in the niche space. The company has been incurring operating losses due to limited revenues from the pharmaceutical operations and sale of the 4Kscore test.
OPK SYK VEEV ABMD GHDX SGH

2
Veeva Systems' Development Cloud Platform Picked by Idorsia

2018-07-17 zacks
Shares of Veeva Systems (VEEV - Free Report) climbed 3.5% to $82.23 following the company’s recent collaboration with Idorsia Pharmaceuticals Ltd.
RCIAF NOBGF RCI N21 SYK VEEV NOBGY GHDX SGH

10
Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?

2018-07-16 zacks
Boston Scientific Corporation (BSX - Free Report) recently renamed the Rhythm Management business as Rhythm and Neuro, which now includes Cardiac Rhythm Management (CRM), Electrophysiology (EP) and Neuromodulation (previously part of the MedSurg segment). This segment emerged as the second largest contributor to Boston Scientific’s top line on solid sub-segmental performance in the last reported quarter.
ALGN POOL BSX GTT SYK GHDX

5
Here's Why You Should Add Inogen (INGN) to Your Portfolio

2018-07-16 zacks
Inogen Inc. (INGN - Free Report) is currently a top performer in the MedTech space. Improved price performance and strong fundamentals instill investors’ optimism in the stock. It’s time you take advantage of the stock price appreciation.
POOL INGN GTT SYK ABMD GHDX

5
Here's Why You Should Invest in DaVIta (DVA) Stock Right Now

2018-07-16 zacks
DaVita Inc. (DVA - Free Report) is currently one of the top-performing stocks in the MedTech space. Solid performance by the Kidney Care unit and strong fundamentals are major positives at the moment.
POOL GTT SYK GHDX

4
QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

2018-07-13 zacks
On Jul 12, we issued an updated research report on QIAGEN N.V. (QGEN - Free Report) . The company's business is expected to get a boost from its flourishing molecular diagnostic market, international expansion, extended test menu and growth-driving strategic collaborations.
ALGN SYK GHDX

7
Boston Scientific (BSX) Q2 Earnings: Is a Beat in Store?

2018-07-13 zacks
Boston Scientific Corporation (BSX - Free Report) is scheduled to report second-quarter 2018 results before the opening bell on Jul 25.
RMD BSX SYK RMD HSIC

4
Here's Why You Should Add Edwards Lifesciences (EW) Now

2018-07-13 zacks
Edwards Lifesciences Corporation (EW - Free Report) has been gaining investor confidence on consistently positive results. Over the past six months, the stock has gained 21.8% against its industry’s 17.8% decline. Also, the company has outperformed the S&P 500’s 0.7% increase.
ALGN SYK SAM GHDX EW

4
Here's Why You Should Invest in BioScrip (BIOS) Right Now

2018-07-12 zacks
BioScrip, Inc. (BIOS - Free Report) has been gaining investors’ confidence on consistently positive results. Over the past three months, the company’s stock has outperformed its industry. The stock has gained 23.8%, compared with the industry’s 11%. The company has also outperformed the 5.5% gain of the S&P 500 market as well.
ALGN SYK BIOS GHDX

14
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?

2018-07-12 zacks
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. We expect this strength to further get reflected in second-quarter 2018 results, scheduled for release on Jul 18.
ABT RMD SYK MCK RSMDF RMD ABT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to SYK / Stryker Corp. on message board site Silicon Investor.

Sykes Enterprises (SYKE) Stryker Corporation (SYK)
CUSIP: 863667101